Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Squeezing the arms as a treatment for acute ischemic stroke.

Frontiers in strokeĀ·2026
Same author

Sedation vs General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke: The SEGA Randomized Clinical Trial.

JAMA neurologyĀ·2025
Same author

Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.

NeurologyĀ·2025
Same author

Intravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy: A Subgroup Analysis of the MOST Randomized Clinical Trial.

JAMA neurologyĀ·2025
Same author

Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial.

StrokeĀ·2025
Same author

Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.

The New England journal of medicineĀ·2024

Related Experiment Video

Updated: Jun 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Intravenous thrombolytics for ischemic stroke.

Andrew D Barreto1

  • 1Department of Neurology, Stroke Division, Neurosonology Laboratory, University of Texas-Houston Medical School, Houston, TX 77030, USA. andrew.d.barreto@uth.tmc.edu

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|June 4, 2011
PubMed
Summary

Intravenous thrombolytics are used to treat acute thrombosis, including ischemic stroke, by aiming to restore blood flow. Balancing clot lysis with hemorrhage risk remains a key challenge in stroke treatment.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

Related Experiment Videos

Last Updated: Jun 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Intravenous (IV) thrombolytics have a long history in treating acute thrombosis, initially for coronary thrombosis.
  • Their application has expanded to other conditions, notably ischemic stroke, adapting cardiology treatment paradigms.
  • The primary goal is to recanalize occluded arteries and restore perfusion to salvageable brain tissue.

Purpose of the Study:

  • To review the established and emerging use of IV thrombolytics in acute ischemic stroke.
  • To discuss the challenges and ongoing research in optimizing thrombolytic therapy for stroke.
  • To highlight the critical balance between achieving reperfusion and mitigating hemorrhage risk.

Main Methods:

  • Review of historical adoption of IV-thrombolysis for ischemic stroke, referencing key studies like the National Institute of Neurological Disorders and Stroke study.
  • Discussion of the development and testing of novel IV-thrombolytic agents.
  • Evaluation of ongoing research into adjunctive treatments for acute ischemic stroke.

Main Results:

  • Widespread adoption of IV-thrombolysis for ischemic stroke began in the late 1990s.
  • Despite development, no new IV-thrombolytics have surpassed placebo efficacy in trials since initial adoption.
  • Research continues to explore adjunctive treatments to improve outcomes.

Conclusions:

  • IV-thrombolysis remains a cornerstone for acute ischemic stroke treatment, mirroring cardiac interventions.
  • The efficacy of new thrombolytic agents has not yet surpassed established treatments.
  • Future efforts focus on enhancing reperfusion strategies while carefully managing the risk of intracranial hemorrhage.